Kazutaka Oda, Hideyuki Hayashi, Keiichi Yamamoto, Shoji Kondo, Tomomi Katanoda, Shinichiro Okamoto, Toshikazu Miyakawa, Eisaku Iwanaga, Kisato Nosaka, Tatsuya Kawaguchi, et al. Antibiotic spectrum coverage scoring as a potential metric for evaluating the antimicrobial stewardship team activity: a single-center study. Infection control and hospital epidemiology. 2024. 45. 11. 1-9
Kazutaka Oda, Shinichiro Okamoto, Eisaku Iwanaga, Hirotomo Nakata. Investigating the WHO's AWaRe classification for assessing antimicrobial stewardship programs: A single-center study. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2024
Noriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura, Naoki Watanabe, Maho Ishikawa, Hitomi Nakayama, Eriko Sato, Takayuki Tabayashi, Toru Mitsumori, Tomoiku Takaku, et al. Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group. International journal of hematology. 2024. 120. 1. 60-70
Hiro Tatetsu, Miho Watanabe, Jun Liu, Kenji Tokunaga, Eisaku Iwanaga, Yoshihiro Komohara, Emily Thrash, Mahmoud A Bassal, Masao Matsuoka, Daniel G Tenen, et al. Dissecting the cell of origin of aberrant SALL4 expression in myelodysplastic syndrome. Clinical and translational medicine. 2023. 13. 8. e1327
Michihide Tokuhira, Yuta Kimura, Takayuki Tabayashi, Naoki Watanabe, Shun Tsuchiya, Tomoiku Takaku, Noriyoshi Iriyama, Eriko Sato, Tomonori Nakazato, Toru Mitsumori, et al. Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects. International Journal of Hematology. 2023
